Evidence map›Paper›PMID 36192502›Full record

ReviewNature reviews. Urology2023

Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.

Sze Kiat Tan, Helen Y Hougen, Jaime R Merchan, Mark L Gonzalgo, Scott M Welford

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sze Kiat Tan *Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.
Helen Y Hougen *Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0003-3141-6474
Jaime R MerchanDepartment of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Mark L GonzalgoDepartment of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.
Scott M WelfordDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. Scott.welford@med.miami.edu.ORCID 0000-0002-9579-4223
University of Miami · US

Funding

Adipokine Signaling as a Therapeutically Targetable Driver of Tumor MetabolismR01CA254409 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WELFORD, SCOTT MICHAEL · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA254409
6 · The paper itself

Abstract

Lipid droplet formation is a defining histological feature in clear-cell renal cell carcinoma (ccRCC) but the underlying mechanisms and importance of this biological behaviour have remained enigmatic. De novo fatty acid (FA) synthesis, uptake and suppression of FA oxidation have all been shown to contribute to lipid storage, which is a necessary tumour adaptation rather than a bystander effect. Clinical studies and mechanistic investigations into the roles of different enzymes in FA metabolism pathways have revealed new metabolic vulnerabilities that hold promise for clinical effect. Several metabolic alterations are associated with worse clinical outcomes in patients with ccRCC, as lipogenic genes drive tumorigenesis. Enzymes involved in the intrinsic FA metabolism pathway include FA synthase, acetyl-CoA carboxylase, ATP citrate lyase, stearoyl-CoA desaturase 1, cluster of differentiation 36, carnitine palmitoyltransferase 1A and the perilipin family, and each might be potential therapeutic targets in ccRCC owing to the link between lipid deposition and ccRCC risk. Adipokines and lipid species are potential biomarkers for diagnosis and treatment monitoring in patients with ccRCC. FA metabolism could potentially be targeted for therapeutic intervention in ccRCC as small-molecule inhibitors targeting the pathway have shown promising results in preclinical models.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsFatty AcidsHumansLipid MetabolismLipidsFatty AcidsLipids

Identifiers

PMID36192502
PMCPMC10826284
OpenAlexW4300863255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.